Shamburg News · 8-K filed Oct 19, 2026, 4:50 PM EDT

CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer, Lalezari Steps Down

CYDY · CytoDyn Inc.

  • Leadership change
  • Reg FD disclosure
  • Materiality: high

CytoDyn Inc. appointed Robert E. Hoffman, its Chief Financial Officer, as Chief Executive Officer effective October 20, 2026, and Jacob P. Lalezari resigned as CEO effective the same date to take a non-executive role as Head of Research and Translational Sciences. Hoffman's approved compensation for the fiscal year ending May 31, 2027 includes a base salary of $525,000, a bonus target increase from 40% to 50%, and a grant of options for 2,500,000 shares. Hoffman will also continue as principal accounting officer, and the company furnished a press release and investor presentation dated October 19, 2026.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 5.02, 7.01, 9.01, accession 0001175680-26-000038.

Written from the filing by Shamburg Markets. Figures are as reported by the company.